Cardiometabolic effects of direct-acting antivirals in patients with hepatitis C

Abstract

Hepatitis C virus (HCV) has long been associated with several extrahepatic manifestations, including increased cardiovascular risk. The emergence of direct-acting antivirals (DAAs) has allowed us to evaluate the potential reversal of these manifestations after successful treatment. Therefore, many studies have provided significant takeaways regarding the positive effect of DAAs therapy on insulin resistance, type 2 diabetes mellitus, cardiovascular disease and atherosclerosis. In contrast, studies have shown detrimental effects on lipid metabolism and indeterminate results regarding renal function and uric acid metabolism. Nevertheless, as more and more patients achieve sustained virological response, the effects of HCV eradication on cardiometabolic processes will be extensively studied, allowing more reliable conclusions on the extent of extrahepatic outcomes.

Keywords: Antivirales de acción directa; Cardiovascular risk; Direct-acting antivirals; Dislipidemia; Dyslipidemia; Función renal; Hepatitis C; Insulin resistance; Renal function; Resistencia a la insulina; Riesgo cardiovascular.